SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novavax NVAX
NVAX 8.400-0.4%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: recycled_electron who wrote (142)6/3/2022 4:57:25 PM
From: Paul Senior1 Recommendation

Recommended By
recycled_electron

   of 166
 
Yet again I add to my most losing position. (buying more today)

If the game is rigged against NVAX, as many on the internet believe, then the myocarditis card will be played, and the approval will not be granted. As justification, a delay will be issued until further information can be gathered and evaluated.

On the other hand, the myocarditis numbers are within what can be expected from a flu apparently - and from a vaccine as when considering what has happed with other Covid vaccines which have been approved - so in my view, the benefits of approving outweigh the small number of myocarditis issues we see which may or may not be attributed to the NVAX vaccine.

I ask myself, what is the most beneficial outcome - most beneficial to most stakeholders? i say it is to have NVAX approved and allow the vaccine to be made available to those who might want it. I am betting that's how our esteemed government officials who are objective and non-corrupted (assuming that they exist and are in the majority) will vote.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News